SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Democratic midterm gains, with traders expecting Democrats to control Congress, have focused attention on DJT as a political setback for Trump and a potential headwind for the company. The conversation is overwhelmingly bearish, with some traders expecting more political and policy pressure, while others argue Trumps veto power could limit the impact.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Democrats midterm gains and control of Congress are driving a volatile SPY conversation, with traders focused on an overnight drop followed by a sharp rebound. Views diverge on whether gridlock and reduced uncertainty support stocks or whether potential scrutiny of AI and data-center spending poses a broader-market risk.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs earnings beat and upbeat outlook, driven by strong AI and data-center demand, sparked bullish discussion about its growth prospects. Traders also questioned whether the rally can hold, citing valuation, cash-flow and PC-market concerns, as well as speculation that election results could bring tighter data-center restrictions.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Democratic gains in the midterms triggered a sharp QQQ selloff followed by a strong rebound, as traders debated whether reduced election uncertainty and divided government would support stocks or whether potential limits on AI and data-center expansion could weigh on tech shares. The community remains split between calling the recovery a relief rally and viewing it as a temporary bounce amid policy concerns.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos stronger-than-expected quarterly results and raised full-year outlook, supported by momentum in the Wegovy pill, are fueling hopes for a recovery. Bulls see oral-drug growth and international expansion offsetting competitive pressure, while bears remain concerned about Lilly, pricing and management execution.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros strong quarterly results and higher full-year outlook, driven by AI-server demand, are the main focus. Traders are upbeat about growth but debate whether thin margins, cash conversion and lingering credibility concerns justify the stocks muted, volatile reaction; some also speculate that election-related AI regulation could weigh on the sector.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Attention centers on fears that AI-assisted, open-source clones of Adobes creative apps could weaken its subscription moat, reinforced by a Wells Fargo downgrade citing competitive and growth concerns. Bearish traders see a threat to paid users, while bulls argue Adobes enterprise workflows, ecosystem, and cash generation are harder to replicate.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingos Q3 results are driving attention: faster daily-user growth, revenue and bookings above expectations, and a raised outlook are set against an EPS miss. Traders are split between welcoming the growth and guidance and questioning valuation, profitability, and AI-related risks, with shares pulling back after an initial post-earnings pop.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs strong quarterly results and raised outlook, supported by demand for AI data-center connectivity and the Scorpio product ramp, are the main focus. Traders are split over the stocks weak, volatile reaction despite the report, weighing growth prospects against rich valuation and sell-the-news pressure.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

CIFR is drawing attention after its Q3 report showed a revenue miss even as the company began recognizing HPC lease revenue and expanded its Barber Lake lease. The sharp rebound has some traders pointing to an oversold, sector-wide recovery or short covering, while skeptics see a dead-cat bounce and remain concerned about execution and financing risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -64.15% and +5.25%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

CRMD Stock Hits Fresh 52-Week Low On DaVita’s Warning Of Sharp 2027 DefenCath Reimbursement Drop

Equity

DefenCath is CorMedix’s largest revenue driver in the dialysis setting, generating $258.8 million in net sales in 2025 and accounting for a majority of the company's reported full-year revenue of $311.7 million. 

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial OfficerPR NewswireNEW YORK, Oct. 15, 2026NEW YORK, Oct. 15, 2026...

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?

CRMD vs. PRTA: Which Stock Is the Better Value Option?

Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet

The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

CorMedix (CRMD) Upgraded to Buy: Here's Why

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Biotech Momentum Meets a Google AI Shockwave: 4 Stocks Traders Are Watching Now

Biotech momentum is carrying forward, as the three biotechs we covered, Picard Medical (NYSEAMERICAN:PMI), NeOnc Technologies (NASDAQ:NTHI), and CorMedix (NASDAQ:CRMD) continue to move, while Rezolve Ai (NASDAQ:RZLV) has introduced a powerful new AI infrastructure catalyst through Google (NASDAQ:GOOG).

CorMedix (CRMD) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade

The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

These Stocks are Keeping the Heat Up

The market is once again rewarding companies that can produce a combination of real operating progress, identifiable catalysts and a credible path to growth, including NeOnc (NASDAQ:NTHI), Profusa (NASDAQ:PFSA), CorMedix (NASDAQ:CRMD), IP Strategy (NASDAQ:IPST), Haemonetics (NYSE:HAE), Heartflow (NASDAQ:HTFL), and FreeCast (NASDAQ:CAST).

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>DaVita CFO Joel Ackerman said on Thursday that he expected the Medicare add-on payment for DefenCath to drop significantly from the first quarter of 2027 to the second quarter and stay low or decline further through the rest of the year.</li><li>When Medicare pays dialysis centers less for DefenCath, CorMedix typically has to lower the price it charges them.</li><li>CorMedix has guided for lower DefenCath revenue in 2026, $175–$195 million versus $258.8 million in 2025, as it navigates the post-TDAPA transition.</li></ul>Shares of CorMedix (CRMD) tumbled nearly 26% on Friday, hitting a fresh 52-week low, as investors reacted to remarks from dialysis giant DaVita (DVA) about how Medicare payments for CorMedix’s flagship product, DefenCath, will evolve.DefenCath is a solution used to help prevent serious bloodstream infections in dialysis patients. Dialysis companies like DaVita are CorMedix’s biggest customers. The solution had benefited from a temporary Medicare add-on payment known as TDAPA. That more favorable window ended in mid-2026. Now the product receives a smaller ongoing add-on that Medicare recalculates each quarter.“The important thing to realize on that is because it’s a post-TDAPA add-on payment, it will get recalculated every quarter based on updated volume and updated ASP. Our current expectation is that number will drop significantly from Q1 to Q2 and stay low or continue to decline through the back half of 2027,” DaVita CFO Joel Ackerman said on Thursday on the company’s third-quarter earnings call.When Medicare pays dialysis centers less for DefenCath, CorMedix typically has to lower the price it charges them. Ackerman’s warning that the payment will fall sharply after early 2027 increased fears that pricing pressures are here to stay.<h2 class="st-heading-2">Ongoing Pressure On The Stock</h2>CorMedix has guided for lower DefenCath revenue in 2026, $175–$195 million versus $258.8 million in 2025, as it navigates the post-TDAPA transition, even as overall company revenue guidance remains higher at $325–$345 million.However, according to data from Koyfin, all six analysts covering the stock rate it 'Buy' or higher, likely because the company has more approved drugs under its wing, including Rezzayo and Vabomere. Defencath, however, is the company’s largest revenue driver in the dialysis setting, generating $258.8 million in net sales in 2025 and accounting for a majority of the company's reported full-year revenue of $311.7 million.<h2 class="st-heading-2">How Did CRMD Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$CRMD" data-symbol-id="CRMD" href="https://stocktwits.com/symbol/CRMD" target="_blank">CRMD stock</a> jumped from 'bullish' to 'extremely bullish' territory over the past 24 hours, while message volume increased from 'normal' to 'high' levels.A Stocktwits user recommended that CorMedix must undertake more share buybacks to support its share price instead of pursuing another acquisition.<stembedurl>https://stocktwits.com/ragman1/message/667787794</stembedurl>Another user termed the selloff a result of panic selling.<stembedurl>https://stocktwits.com/AMP19/message/667784051</stembedurl>CRMD stock has dropped 50% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tgtx-stock-hits-fresh-52-week-high-ahead-of-earnings-amid-buyout-buzz/cZULRP2R9cR">TGTX Stock Hits Fresh 52-Week High Ahead Of Earnings Amid Buyout Buzz</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

DefenCath, CorMedix’s first commercial product, is an antimicrobial drug designed to reduce catheter-related bloodstream infections in patients with kidney disease.

Current Price	$5.56
Prev Close	$5.39
Open	$5.35
Dividend Yield	0.00%
50-Day Moving Average	$7.69
Beta	1.08
Avg. Volume	1.44M
PE Ratio	2.64

52-Week High	$13.02
52-Week Low	$5.30
Market Capitalization	$420.12M
EPS (Annual)	$2.03
Price to Book	0.94
Revenue Per Employee	$1.63M

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRMD Fundamentals